Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Outstanding Shares: 1,563,353,283 common shares (as of Sept 30, 2003)
Abbott Laboratories is a global healthcare company engaged in the discovery, development, manufacture, and sale of pharmaceutical, diagnostic, hospital, and nutritional products. The company operates through five reportable segments: Pharmaceutical Products, Diagnostic Products, Hospital Products, Ross Products, and International.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2003 | Nine Months Ended Sept 30, 2003 |
|---|---|---|
| Net Sales | $4,845.9 million | $14,150.0 million |
| Net Earnings | $761.2 million | $1,808.8 million |
| Diluted EPS | $0.48 | $1.15 |
| Operating Earnings | $911.0 million | $2,216.7 million |
| Net Cash from Operating Activities | N/A | $3,099.7 million |
| Cash and Cash Equivalents (End of Period) | $1,681.9 million | $1,681.9 million |
| Short-term Borrowings | $803.8 million | $803.8 million |
| Long-term Debt | $3,908.3 million | $3,908.3 million |
| Gross Profit Margin (9 Months) | 51.8% | 51.8% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.6% for the quarter and 10.2% for the nine-month period compared to 2002. Growth was driven by unit volume and a weaker U.S. dollar, which positively impacted sales by approximately 3.0% for the quarter and 3.2% for the nine months.
- Profitability: Net earnings increased 5.7% for the quarter ($761.2M vs. $720.1M) but decreased 16.5% for the nine months ($1.81B vs. $2.17B). The nine-month decline was primarily due to a $622 million pre-tax charge related to the settlement of the Ross enteral nutritional investigation.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 32.9% for the nine months, largely due to the $614 million litigation settlement charge. Excluding this charge, SG&A increases were driven by marketing support for new products like Humira.
- Cash Flow: Net cash from operating activities increased to $3.1 billion for the nine months ended Sept 30, 2003, compared to $2.98 billion in the prior year period.
- Debt Structure: Short-term borrowings decreased significantly from $1.93 billion at year-end 2002 to $803.8 million at Sept 30, 2003, as the company refinanced short-term yen-denominated debt into long-term bonds.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and Charges
- Ross Enteral Nutritional Settlement: Abbott accrued a $622 million charge ($614M in SG&A, $8M in Cost of Products Sold) to settle a government investigation. The $614 million payment was made in Q4 2003, funded by third-quarter borrowings.
- Acquisitions: Abbott acquired ZonePerfect ($160M), Integrated Vascular Systems ($65M), Spinal Concepts ($166M), and JOMED assets ($68M) in 2003. These resulted in $100.2 million in acquired in-process R&D charges for the nine-month period.
- Product Sales: Recorded a $31 million gain from the sale of U.S. rapid diagnostic test portfolio rights in Q3 2003.
Outlook and Management Commentary
- Humira Launch: Following FDA approval in late 2002 and EU approval in Sept 2003, worldwide sales of Humira are forecasted to exceed $250 million in 2003. U.S. sales for the first nine months were $151 million.
- Spinoff Plan: In August 2003, Abbott announced a plan to spin off its core hospital products business into a separate publicly traded company, expected in the first half of 2004.
- Tax Rate: The effective tax rate for the nine months ended Sept 30, 2003, was 27.4%, elevated by the settlement charge. Management anticipates the rate for the final quarter of 2003 to be approximately 24.0%.
Risks and Contingencies
- Legal Proceedings: Abbott faces various antitrust suits regarding pharmaceutical pricing, patent litigation (e.g., Hytrin, Depakote, TriCor), and product liability suits (e.g., OxyContin, Meridia). Management believes outcomes, excluding the Ross settlement, will not have a material adverse effect.
- FDA Consent Decree: Ongoing compliance issues with the FDA regarding diagnostics manufacturing in Lake County, Illinois, could result in additional costs or revenue loss if full conformance is not achieved.
- Legislative Issues: Potential government legislation could reduce prices or price increases for medical products.
Investor Verification Checklist
- Settlement Payment Impact: Verify the cash outflow impact of the $614 million Ross settlement payment made in Q4 2003 on year-end liquidity.
- Spinoff Timeline: Monitor progress on the planned spinoff of the Hospital Products business scheduled for H1 2004.
- FDA Compliance Status: Track the outcome of the FDA re-inspection of Lake County diagnostics facilities to assess potential future charges or revenue restrictions.
- Humira Sales Trajectory: Confirm if Humira sales meet the forecasted $250 million for 2003, particularly regarding international non-patient named basis programs starting in Q4.
- Debt Refinancing: Review the terms and interest rate exposure of the new long-term yen-denominated bonds issued in Q4 2003.